Achieving Impact Award from the University of Sussex for their Industrial Informatics and Signal Processing Research Group (June 2015)

The TexRAD Cancer management technology is being used as a research tool in seven of the G8 Countries; FDA and CE approvals for clinical use are imminent.

Former Vice Chancellor Professor Michael Farthing (RHS); Pro Vice Chancellor for Research & Deputy VC Professor Michael Davies (LHS); Professor Chris Chatwin (Centre); Dr Rupert Young (Centre Left); Dr Balaji Ganeshan (Centre Right) - 16th June 2015

Research to address the detection of weak structured signals from within highly variable cluttered imagery is being used to identify textural variations in Computed Tomography (CT) X-ray images of organ tissue. The technology has been spun out into a company, TexRAD Ltd, that was recently taken over by Feedback plc, an AIM listed stock-market company. TexRAD uses novel image processing technology as a means of detecting tissue abnormalities, typically cancer, assessing response to treatment, and predicting patients’ chances of survival. The detection process is being assessed via clinical research use in leading international Cancer research institutions using existing historical data in Europe, Asia and America. Regulatory approval for mainstream clinical use is imminent. Once regulatory approval has been gained TexRAD will be used for: cancer diagnosis, prognosis and treatment planning on current patients, which will save lives, generate a significant revenue stream and greatly increase the value of Feedback plc. TexRAD is Feedback’s only product.